Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. - Wikidata - wikimedia - TriplyDB

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q33741548

about

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Dietary macronutrient and energy intake and urinary incontinence in women.Benign prostatic hyperplasia: from bench to clinic Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production Association of variants in genes related to the immune response and obesity with BPH in CLUE II Dietary macronutrient intake and lower urinary tract symptoms in women.Increased risk of benign prostate hyperplasia in sleep apnea patients: a nationwide population-based study.Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume.Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.Future perspectives of prostate cancer therapy.Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Role of interleukins, IGF and stem cells in BPH Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.A green and black tea extract benefits urological health in men with lower urinary tract symptoms.The link between benign prostatic hyperplasia and prostate cancer.Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection?Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study.The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2.Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.DNMT1 regulates IL-6- and TGF-β1-induced epithelial mesenchymal transition in prostate epithelial cells.Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women.Inhibitory Effect of Thymoquinone on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats.The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.Office evaluation of male patients with lower urinary tract symptoms.Epidemiology of clinical benign prostatic hyperplasia.Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat.Metabolic syndrome and benign prostatic hyperplasia: An update.Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia

P2860

Q31001228-930338C9-356C-4B5E-BE1B-07C6F880D076 Q33880849-70F4FD52-B06F-43F8-955E-D1388E0149B9 Q34216723-AEC153AD-7D10-4835-A4F3-F785C6540155 Q34448124-F7A3B01F-E1B4-48A2-B0A3-4F22ACCD033B Q34490355-F35DD5A0-EEC5-4F6C-A5BF-B001BF83A02A Q34959268-227258B6-4852-4EF6-AB17-19548406E8A8 Q35131466-46A2AA79-90FA-4987-8DB7-811E6998C9E9 Q35190607-4C2592A2-601D-4F1D-A506-502C40AE5541 Q35318562-1060C0A6-E533-4E2D-BD93-0E5879A7F3FC Q35687087-8632DD53-8BD8-4A97-9BA1-6E6FDA1844E4 Q36059979-802F0106-FE94-48C7-BA3E-BF2C65D36B9B Q36076453-0FE2B2FE-DA58-4F05-A1A8-D0F2700D7BC1 Q36383682-AE0964A1-D1ED-4414-A7BE-4BB9C247B372 Q37127902-1E81088D-DBF9-47F4-925F-31455E5FFC64 Q37416239-8D2BA1E5-20B3-40D0-98F8-C9AEBEC7A8F4 Q37618958-4EE77C20-4BBE-4C5B-B43A-5C29002B7CC6 Q37730835-2653E07F-1685-4EFD-84DD-9D9366C5BEC7 Q38061029-891D0179-E792-4B96-A424-8F31851FCD92 Q38077302-A3CFCF75-6FDC-4CA5-BBB8-53B834CC3727 Q38098399-AFC54AA7-DCC2-4D5E-A77E-BFED5F8FCC0C Q38692706-170FF6E1-1ED8-4459-B6A6-24A73F5ADFBE Q38711334-8D4BF737-D05A-418E-92A5-E1A3AFBBD570 Q38798979-95F45751-8BE0-46DD-912C-5CC8DFAC9571 Q39092660-E6DD4DC4-4D2A-4141-9475-E8D388591C8E Q39127025-3D4171AC-DB48-43CB-82E8-18A56E5E6DC0 Q39264604-6755048B-1356-4408-8981-C2A43B4A8BAE Q39981630-A53FB915-C9D4-4AA2-B031-81659ABF46EF Q40300137-BD8D35CF-2CFF-4569-AA8E-0D43F1A323B7 Q42264513-0BF53555-8DC5-4522-8CC3-7021B7BFA9A7 Q45901789-0040B4B0-7F0D-4593-8542-0182B1C9D050 Q48271761-67C4CF06-6F37-46F5-96FC-32E2DEC7CBEA Q49117373-BFC08AEA-FC09-4A33-B160-4343D81F2D1C Q51317315-F384121B-51DB-4D72-BA17-0568509F1328 Q51776590-F74F2C1E-D206-4E6D-8E7D-DBAC7CDC5B8C Q52923562-404EEFE4-5994-4171-A83C-52890992DDC0 Q55345009-F294B319-BC94-4EFE-8F51-BA90729B82E8 Q56898498-FB90859C-98D3-451A-8640-911A4CA2A492

P2860

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q33741548

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@ast

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@en

type

label

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@ast

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@en

prefLabel

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@ast

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@en

P1433

Q33741548-16F64A95-8BB9-4945-A3A2-D0D77412BFA7

P1476

Q33741548-B27AB572-F8B7-4AA0-B009-AB376748FA46

P2093

Q33741548-4530D677-7B14-4044-BF94-C9DD6E5C956A

Q33741548-5AD8959E-F5EC-419B-BC04-1EB2F88C6F2E

Q33741548-6F398A8F-C451-48F3-A722-A3071B03257B

Q33741548-A22814CA-CC58-490E-8CA6-64A423A84A92

Q33741548-B1F79E3E-E289-4149-AAD6-B9CD7FE55293

Q33741548-C8ACF560-47A7-4769-B63B-58258935EEDD

Q33741548-D66EF7D4-3D51-4A3A-BBFB-FA5BE65EE650

P2860

Q33741548-00DACED5-B73C-4010-A5AB-2D2A137452A9

Q33741548-16B9C1F4-D6DB-4501-837A-AA912AA689F1

Q33741548-176365A4-98E6-4DC9-8106-641D4A52469E

Q33741548-182AF2E2-B1F5-4E72-A443-B8E5C8620365

Q33741548-20106A2A-58D9-4A0D-9AD7-B75449145C67

Q33741548-28DD84B0-EA65-4AE4-9469-E20CA1D4780B

Q33741548-29E64F26-AB71-4C25-BF56-28B69B4BE0F6

Q33741548-2DAFCE89-F4AE-4B95-AE72-FC6F1EE3CECE

Q33741548-360E3F94-5990-427D-ACF9-C20D9D3F6DA2

Q33741548-3C43B0E8-01BD-424E-8462-AA6F4D0DC999

P304

Q33741548-BFBAFCE5-B130-407C-BDA0-F77772A72883

P31

Q33741548-F455E6F9-0B52-4CFE-AB49-CD8E74B532F1

P356

Q33741548-A354E116-C3BA-430B-90DB-2358B3EFFF1B

P407

Q33741548-17A7A17A-D401-4854-A206-88D07E210388

P433

Q33741548-30CA0603-0826-404E-8B3D-2406CEA49958

P478

Q33741548-B2259B57-CEC3-4D53-AF49-F1E99ECF41E8

P50

Q33741548-A8E3E5F6-449D-4AC9-9454-627A14F2DF78

P577

Q33741548-3521C9DD-34F1-4510-8AEC-05930998543D

P5875

Q33741548-9505DBA2-E692-4AF0-8156-2B8AD437695E

P698

Q33741548-C9BE307B-79C5-4EFF-AE91-6D1496B7E935

P921

Q33741548-C96DAC9D-1E9C-422F-BF62-295AA2DF613B

P932

Q33741548-0036DE3A-5846-4E71-B2AE-AE35CB2891CE

P356

P1433

American Journal of Epidemiology

P1476

Biomarkers of systemic inflamm ...... state cancer prevention trial.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Daniel W Lin

http://www.w3.org/2001/XMLSchema#string

Emily White

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Jeannette M Schenk

http://www.w3.org/2001/XMLSchema#string

Marian L Neuhouser

http://www.w3.org/2001/XMLSchema#string

Mario Kratz

http://www.w3.org/2001/XMLSchema#string

P2860

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Asymptomatic inflammation and/or infection in benign prostatic hyperplasia.

New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States.

Pathology of benign prostatic hyperplasia.

The natural history of benign prostatic hyperplasia: what have we learned in the last decade?

Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.

Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis.

Adipokines: inflammation and the pleiotropic role of white adipose tissue.

P304

571-582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/AJE/KWP406

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Kristal

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416733

http://www.w3.org/2001/XMLSchema#string

P698

20142396

http://www.w3.org/2001/XMLSchema#string

P921

P932

2842217

http://www.w3.org/2001/XMLSchema#string